AC Immune

CompanySwitzerland

AC Immune develops 6 assets, the furthest in phase 2 (ACI-7104.056 in early-onset Parkinson disease 6). Mostly vaccine and small molecule acting on proteostasis, APP and MAPT; based in Switzerland.

Assets
6
Furthest
Phase 2
Trials
8
Signals
0

Pipeline

6

  • ACI-7104.056

    Active immunotherapy eliciting an antibody response against pathological alpha-synuclein aggregates.

    Phase 2VaccineSNCAProteostasisearly-onset Parkinson disease 6Parkinson's disease

  • ACI-19764

    Inhibits NLRP3 inflammasome activation to reduce downstream inflammatory cytokine release.

    Phase 1Small moleculeNLRP3NLRP3 inflammasomecardiovascular riskobesity

  • ACI-24

    Liposomal anti-amyloid-beta vaccine designed to elicit antibodies against amyloid-beta to prevent or clear plaques

    Phase 1VaccineAPPProteostasisDown syndrome

3 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms7
  • Trials8
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 19 sources

Intelligence